351343-83-4

Upstream product

• 351343-82-3 ethyl 3-(1-(4-fluorophenyl)cyclohexyl)propanoate 
• 1307812-11-8 (E)-ethyl 3-(1-(4-fluorophenyl)cyclohexyl)acrylate 
• 71486-43-6 1-(4-fluorophenyl)cyclohexanecarbonitrile 
• 351343-80-1 1-(4-fluorophenyl)cyclohexane-1-carbaldehyde 

Downstream Products

• 1307812-92-5 2-(2-(1-(4-fluorophenyl)cyclohexyl)ethyl)naphtho[1,2-d]oxazole-7-carbaldehyde 
• 1307812-91-4 1-(2-(2-(1-(4-fluorophenyl)cyclohexyl)ethyl)naphtho[1,2-d]oxazol-7-yl)ethane-1,2-diol 
• 1307812-90-3 2-(2-(1-(4-fluorophenyl)cyclohexyl)ethyl)-7-vinyl-4,5-dihydronaphtho[1,2-d]oxazole 
• 1307815-63-9 3-(1-(4-fluorophenyl)cyclohexyl)propanoyl chloride 
• 1307810-01-0 1-((2-(2-(1-(4-fluorophenyl)cyclohexyl)ethyl)naphtho[1,2-d]oxazol-7-yl)methyl)azetidine-3-carboxylic acid 

Relevant academic research and scientific papers

SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS

Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are a

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.